Highest-materiality recent filing
Phathom Q2 revenue $74.3M (+88% YoY); net loss narrows to $17.6M; initiates Phase 3 NERD trial
Record Q2 net revenue $74.3M, up 88% YoY and 27% QoQ; operating expenses $63.1M, down 33% YoY.
Phathom completes enrollment in Phase 2 EoE trial; topline data expected Q4 2026
Enrolled 95 adults at 41 US sites in pHalcon-EoE-201 Phase 2 trial of VOQUEZNA for eosinophilic esophagitis.
Phathom stockholders elect three Class I directors, ratify EY, approve say-on-pay
Elected Steven Basta, Theodore R. Schroeder, Mark Stenhouse as Class I directors: 42.7M, 42.6M, 41.2M votes for respectively.
Phathom Pharma Q1 net rev $58.3M (+104% YoY); maintains FY 2026 op profitability guidance
Q1 net revenues $58.3M vs $28.5M YoY; net loss $30.4M vs $94.3M YoY.
Q4 net revenues $57.6M; FY2025 net revenues $175.1M, a 217% increase over FY2024.
Phathom Pharmaceuticals prices $130M public offering of common stock and pre-funded warrants
6,875,000 shares of common stock at $16.00/share and pre-funded warrants for 1,250,078 shares at $15.999/warrant.
Q4 2025 net revenues expected ~$57-58M; full year 2025 net revenues ~$174.5-175.5M.
Phathom Pharmaceuticals doses first patient in Phase 2 EoE trial of VOQUEZNA
First patient dosed in Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) for eosinophilic esophagitis in adults.
Phathom Q3 revenue $49.5M, up 25% QoQ; net loss $30M; FY guidance raised to $170-175M
Net revenue of $49.5M in Q3 2025, up 25% from Q2 and from $16.4M in Q3 2024.
Phathom publishes Phase 3 NERD data showing VOQUEZNA improves nocturnal GERD symptoms
At week 4, VOQUEZNA 10 mg and 20 mg achieved 59.9% and 56.4% heartburn-free nights vs 43.3% placebo (nominal p<0.0001).
Phathom Pharmaceuticals appoints Sanjeev Narula as CFO and Business Officer effective Oct 6, 2025
Sanjeev Narula named Chief Financial and Business Officer; replaces Robert Breedlove as principal financial officer.
Phathom Q2 revenue $39.5M, up from $7.3M YoY; 580k+ VOQUEZNA scripts filled
Net revenues $39.5M in Q2 2025 vs $7.3M in Q2 2024; net loss $75.8M vs $91.4M YoY.
FDA Orange Book corrected; VOQUEZNA NCE exclusivity confirmed through May 2032
FDA updated Orange Book to show full 10-year NCE exclusivity for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets.
PHAT shareholders elect two directors, ratify EY, approve say-on-pay at annual meeting
Heidi Kunz elected Class III director with 34,023,182 for, 451,384 withheld; James Topper with 26,884,171 for, 7,590,395 withheld.
FDA grants Phathom citizen petition; VOQUEZNA exclusivity extended to May 2032
FDA approved Phathom's 2024 citizen petition to correct Orange Book for VOQUEZNA (vonoprazan) tablets.
Phathom Q1 net revenue $28.5M, net loss $94.3M; cuts costs, exec changes, targets 2026 profit
Net revenue $28.5M (up from $1.9M YoY); net loss $94.3M ($77.1M non-GAAP adjusted).
Phathom Pharmaceuticals appoints Theodore R. Schroeder to board, effective April 16, 2025
Schroeder appointed as Class I director, term expiring at 2026 annual meeting; will serve on audit committee.
CEO transition at Phathom: Steven Basta appointed, Terrie Curran resigns effective March 31, 2025
Steven Basta appointed CEO, President and Class I director effective April 1, 2025; Terrie Curran resigned for personal reasons.
Phathom Pharma Q4 revenue $29.7M; VOQUEZNA prescriptions up 81% QoQ
FY2024 net revenue $55.3M from VOQUEZNA launch; Q4 revenue $29.7M (81% increase vs Q3).
Phathom files Citizen Petition to correct VOQUEZNA Orange Book exclusivity to May 2032
Petition requests FDA correct VOQUEZNA tablet listings to reflect 10-year NCE exclusivity ending May 3, 2032.
Net revenues $16.4M for Q3 2024 (vs $7.3M Q2 2024); no revenues in Q3 2023.
Phathom Pharmaceuticals prices $130M stock/warrant offering; net proceeds ~$121.7M
8,695,652 shares at $11.50/share and pre-funded warrants for 2,608,922 shares at $11.499/warrant.
Phathom Q2 revenue $7.3M, prescriptions up 184%; VOQUEZNA gets FDA approval for Non-Erosive GERD
Net revenues $7.3M in Q2 2024 vs $1.9M in Q1 2024; no Q2 2023 revenue due to launch in late 2023.
Phathom gets FDA approval for VOQUEZNA to treat heartburn in Non-Erosive GERD
FDA approved VOQUEZNA (vonoprazan) 10 mg tablets for relief of heartburn associated with Non-Erosive GERD in adults.
Phathom stockholders elect three Class II directors; ratify E&Y as auditor
Elected Cola (24.1M for), Karbe (25.0M for), Parikh (21.3M for) with 10.8M broker non-votes each.
Phathom posts Q1 net loss $82.9M, revenue $1.9M; VOQUEZNA prescriptions top 17,500
Net loss GAAP $82.9M (non-GAAP adj. net loss $64.8M) vs $37.8M loss Q1 2023; revenue $1.9M from VOQUEZNA launch.
Phathom reports Q4/FY2023 results; VOQUEZNA launch nets $0.7M revenue, cash runway extended to 2026
Q4 net revenue $0.7M from VOQUEZNA launch; cumulative prescriptions over 14,000 as of Feb 23, 2024.
Express Scripts adds VOQUEZNA to national formularies for commercial plans
Express Scripts, a leading U.S. PBM, added VOQUEZNA to its national formularies for commercial plans, effective immediately.
Phathom amends bylaws to adopt universal proxy rules and enhance stockholder nomination disclosures
Amended bylaws require compliance with SEC Rule 14a-19 for proxy solicitations supporting non-Board nominees.
Phathom Pharma amends loan agreement, boosts facility to $300M, lowers rate
Fourth Amendment with Hercules Capital increases aggregate loan from $200M to $300M; $40M of Tranche 2 funded at closing.
Phathom's NDA for VOQUEZNA in Non-Erosive GERD accepted by FDA; PDUFA date July 19, 2024
FDA accepted NDA for VOQUEZNA (vonoprazan) for daily heartburn treatment in Non-Erosive GERD.
Phathom launches VOQUEZNA for erosive GERD; H. pylori regimens expected mid-Dec.
VOQUEZNA (vonoprazan) now available in 30-count bottles for erosive GERD treatment and heartburn relief.
Phathom Q3 net loss $43.2M; VOQUEZNA FDA approved for Erosive GERD; Dec launch
Net loss $43.2M in Q3 2023 vs $51.1M in Q3 2022; includes $6.1M stock-based compensation.
FDA approves Phathom's VOQUEZNA for Erosive GERD; triggers $175M payment
FDA approved VOQUEZNA (vonoprazan) for healing, maintenance, and heartburn relief in Erosive GERD.
FDA approves reformulated vonoprazan for H. pylori; launch expected Dec 2023
FDA approved prior approval supplements for reformulated vonoprazan tablets in VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for H. pylori infection in adults.
Phathom submits NDA to FDA for vonoprazan as daily Non-Erosive GERD treatment
NDA for vonoprazan as daily treatment for Non-Erosive GERD in adults submitted to FDA, supported by Phase 3 PHALCON-NERD-301 study.
Phathom submits 6-month stability data for vonoprazan NDA; NVP impurity controlled below limit
Submitted 6-month stability data for reformulated vonoprazan tablets to FDA for Erosive GERD NDA.
Phathom Q2 net loss $41.0M; PDUFA dates Oct/Nov 2023 for VOQUEZNA
Net loss $41.0M in Q2 2023, improved from $50.9M in Q2 2022.
Phathom completes stock option exchange; 99.2% of eligible options surrendered for RSUs
2,406,622 options surrendered (~99.2% of eligible) for 1,203,341 new RSUs at 2-for-1 ratio.
Phathom launches voluntary stock option exchange for RSUs at 2-for-1 ratio
Eligible employees and consultants can exchange outstanding stock options for RSUs at a 2-for-1 ratio (one RSU per two options).
FDA accepts Phathom's vonoprazan NDA resubmission for Erosive GERD; PDUFA date Nov 17, 2023
FDA acknowledged NDA resubmission for vonoprazan, a PCAB, as complete response to the February 2023 CRL.
Shareholders approved amendment eliminating personal liability of officers for monetary damages for breach of fiduciary duty (effective May 26, 2023).
Phathom prices public offering of 11.125M shares at $11.75/share for ~$130.7M gross
Offering of 11,125,000 shares at $11.75/share; gross proceeds ~$130.7M.
Resubmitted vonoprazan NDA for erosive GERD to FDA after February 2023 Complete Response Letter.
Phathom Q1 net loss $37.8M, on track to resubmit Erosive GERD NDA this quarter
Net loss $37.8M vs $40.7M YoY; operating expenses 36% lower than prior quarter due to cost controls after launch delay.
Phathom provides regulatory update on path to resubmit EE NDA in Q2 2023; launch expected Q4 2023
Met with FDA; CRLs solely related to nitrosamine impurity NVP; mitigation includes minor tablet reformulation.
Phathom reports Q4 net loss $55M; FDA meeting in March for vonoprazan resubmission
Net loss Q4 2022 $55.0M vs $35.8M Q4 2021; full year net loss $197.7M vs $143.9M.
Phathom receives FDA complete response letters for vonoprazan NDAs due to nitrosamine impurity
CRL for erosive esophagitis NDA and H. pylori post-approval supplement, citing impurity N-nitroso-vonoprazan (NVP).
Vonoprazan 10 mg and 20 mg both achieved significantly greater 24-hour heartburn-free days vs placebo (46.4% and 46.0% vs 27.5%; p<0.0001).
FDA will not act by Jan 11, 2023 PDUFA date for vonoprazan erosive esophagitis NDA.
The board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Theodore R. Schroeder to the Board as a Class I director, effective April 16, 2025
Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.
Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the “Company”), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.
On September 22, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed James Topper, M.D., Ph.D. to the Board as a Class III director, effective immediately, with an initial term expiring at the 2025 annual meeting of stockholders of the Company.
On April 25, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Frank Karbe to the Board as a Class II director, effective immediately
On March 22, 2022, Phathom Pharmaceuticals, Inc. (the “Company”) announced the appointment of Molly Henderson, 51, as its Chief Financial and Business Officer effective April 5, 2022.
Max materiality 0.90 · Median 0.70 · Most common event earnings